Merck & Co., Inc. vs Redwire Corporation — how do they compare? Merck & Co., Inc. trades at $132.54 (market cap $321.77B), while Redwire Corporation trades at $13.56 (market cap $3.38B). The key difference: Merck & Co., Inc. is far larger — about 95.2× Redwire Corporation's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Redwire Corporation pays none. Which is the better fit depends on your goals.
| MRK | RDW | |
|---|---|---|
Market Cap | $321.77B | $3.38B |
Sector | Health | Technology |
52-Week High | $131.84 | $25.90 |
52-Week Low | $77.60 | $5.06 |
Enterprise Value | $368.53B | $2.91B |
Dividend Yield | 2.61% | — |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Redwire (RDW) trades at $13.65, up 4.04% today, with strong technical momentum as moving averages signal bullish sentiment. The company reported record Q2 2026 revenue of $117.1 million and a growing $542.1 million backlog, though it continues to post significant net losses. Analyst consensus remains overwhelmingly positive with 80% buy ratings and a $17.50 price target, representing 28% upside potential from current levels.
While Redwire shows impressive revenue growth and defense contract momentum, investors face substantial risk from persistent losses, negative cash flow from operations, and high valuation multiples despite unprofitability. The company's pivot toward defense technology provides near-term stability but requires careful monitoring of margin improvement and path to profitability.
Trailing returns across standard periods
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →